Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity-Reference-Cited by-同舟云学术

Anti-SARS-CoV-2 Antibody Levels Measured by the AdviseDx SARS-CoV-2 Assay Are Concordant with Previously Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity

Published:2021-08-18 Issue:9 Volume:59 Page:
ISSN:0095-1137
Container-title:Journal of Clinical Microbiology
language:en
Short-container-title:J Clin Microbiol

Author:

Bradley Benjamin T.¹,Bryan Andrew¹,Fink Susan L.¹,Goecker Erin A.¹,Roychoudhury Pavitra¹^ORCID,Huang Meei-Li¹,Zhu Haiying¹,Chaudhary Anu¹,Madarampalli Bhanupriya¹,Lu Joyce Y. C.¹,Strand Kathy²,Whimbey Estella²,Bryson-Cahn Chloe²,Schippers Adrienne²,Mani Nandita S.²,Pepper Gregory¹,Jerome Keith R.¹³,Morishima Chihiro¹,Coombs Robert W.¹²,Wener Mark¹,Cohen Seth²,Greninger Alexander L.¹³^ORCID

Affiliation:

1. Department of Laboratory Medicine and Pathology, University of Washington Medical Center, Seattle, Washington, USA

2. Division of Infectious Diseases, Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA

3. Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

Abstract

With the availability of widespread SARS-CoV-2 vaccination, high-throughput quantitative antispike serological testing will likely become increasingly important. Here, we investigated the performance characteristics of the recently FDA-authorized semiquantitative antispike AdviseDx SARS-CoV-2 IgG II assay compared to the FDA-authorized antinucleocapsid Abbott Architect SARS-CoV-2 IgG, Roche Elecsys anti-SARS-CoV-2-S, EuroImmun anti-SARS-CoV-2 enzyme-linked immunosorbent assay (ELISA), and GenScript surrogate virus neutralization assays and examined the humoral response associated with vaccination, natural protection, and breakthrough infection.

Publisher

American Society for Microbiology

Subject

Microbiology (medical)

Link

https://journals.asm.org/doi/pdf/10.1128/JCM.00989-21

Reference37 articles.

1. FDA. 2020. COVID-19 vaccines. https://www.fda.gov/emergency-preparedness-and-response/coronavirus-disease-2019-covid-19/covid-19-vaccines. Accessed 4 February 2021.

2. SARS-CoV-2 vaccines in development

3. Convergent antibody responses to SARS-CoV-2 in convalescent individuals

4. Potent Neutralization of MERS-CoV by Human Neutralizing Monoclonal Antibodies to the Viral Spike Glycoprotein

5. Antibody response to SARS-CoV-2 infection in humans: A systematic review

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tixagevimab/cilgavimab (AZD7442/Evusheld) prevent from COVID19 in patients with hematologic malignancies under active chemotherapy;Annals of Hematology;2024-04-28

2. Standardised quantitative assays for anti-SARS-CoV-2 immune response used in vaccine clinical trials by the CEPI Centralized Laboratory Network: a qualification analysis;The Lancet Microbe;2024-03

3. System for classifying antibody concentration against severe acute respiratory syndrome coronavirus 2 S1 spike antigen with automatic quick response generation for integration with health passports;Exploration of Digital Health Technologies;2024-02-28

4. Seroprevalence of SARS-CoV-2 antibodies among Japanese healthcare workers from 2020 to 2022 as assayed by two commercial kits;Scientific Reports;2024-02-07

5. Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy;Transplantation and Cellular Therapy;2024-01